China
Africa
Explore chapters and articles related to this topic
Published in Ronald M. Atlas, James W. Snyder, Handbook Of Media for Clinical Microbiology, 2006
Ronald M. Atlas, James W. Snyder
Use: For the detection and isolation of Bordetella pertussis and Bordetella parapertussis from clinical specimens. The medium is rendered selective by the addition of methicillin. Bordetella pertussis appears as small (<1mm), smooth, pearl-like colonies surrounded by a narrow zone of hemolysis. Bordetella parapertussis appears as brown, nonshiny colonies with a green-black coloration on the reverse side. Bordetella bronchiseptica appears as brown, non-shiny, moderately sized colonies with a roughly pitted surface.
Bordetella pertussis
Published in Firza Alexander Gronthoud, Practical Clinical Microbiology and Infectious Diseases, 2020
Despite mass pertussis vaccination strategies and a 95% uptake rate in infants in developed countries, cyclic epidemics continue to occur every 2–5 years. Increasing incidence of individual cases suggests that current vaccines do not prevent circulation of pertussis, making pertussis arguably the least-well-controlled vaccine-preventable disease. Diagnosis is often late, increasing likelihood of transmission in the community. It is therefore worthwhile to consider the following. Bordetella pertussis and Bordetella parapertussis are the causative agents of pertussis or whooping cough, and infections caused by B. parapertussis tend to be somewhat milder.The bacteria are transmitted by droplets.In susceptible contacts, the B. pertussis transmission rate is close to 90%.In highly vaccinated European countries, the basic reproduction number (R0) is estimated to be around 6.Pertussis continues to circulate in populations where high vaccination coverage of infants and children is achieved because the protection after natural infection and vaccination wanes after several years.Therefore, the epidemiology has shifted whereby pertussis circulates in adults, whereas in the pre-vaccination era, pertussis occurred in infants and children.In patients with longer-lasting coughs, a diagnosis of pertussis should be entertained irrespective of their vaccination status.A carrier state does not exist in pertussis; however, in outbreaks, Bordetella DNA may be detected by PCR in asymptomatic patients.Most hospitalizations and deaths occur in infancy, and in this age group, deaths may not even be diagnosed as pertussis.
Evaluation of the Seegene Allplex™ Respiratory Panel for diagnosis of acute respiratory tract infections
Published in Acta Clinica Belgica, 2019
Stien Vandendriessche, Elizaveta Padalko, Elke Wollants, Charlotte Verfaillie, Bruno Verhasselt, Liselotte Coorevits
In the last decade, several molecular commercial assays have been developed for the simultaneous detection of an array of (mostly viral) respiratory pathogens [2,3]. Some of the assays are random access, e.g. BioFire FilmArray respiratory panel (FA-RP) (bioMérieux, Marcy l’Etoile, France) whereas other are for batch analysis, e.g. FTD® Respiratory Pathogens 21 panel (Fast Track Diagnostics, Sliema, Malta) or Seegene Allplex™ Respiratory panel (Seegene, Seoul, South Korea). The Seegene assay comprises four individual panels (three viral and one bacterial panel), and is able to detect 16 respiratory viruses [adenovirus (ADV), bocavirus, coronavirus OC43/NL63/229E, human enterovirus (HEV), human metapneumovirus (HMPV), influenza A/B, parainfluenza (PIV) type 1/2/3/4, respiratory syncytial virus (RSV) A/B and human rhinovirus (HRV)], three influenza A subtypes (H1, H1 pdm09 and H3) and seven bacteria (Bordetella pertussis, Bordetella parapertussis, Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae and Streptococcus pneumoniae). The assay is based on a novel technology that is able to detect multiple targets in a single fluorescence channel without any post amplification melting curve analysis, enabling more multiplexing per reaction [4]. The present study aimed to challenge the Seegene Allplex™ Respiratory panel by a collection of QCMD quality control samples and clinical samples that were analysed previously with validated routine methods at the laboratories of Ghent University Hospital and AZ Sint-Lucas Ghent, Belgium, together serving 1,600 hospital beds and 2 emergency departments.
A profile of the Simplexa™ Bordetella Direct assay for the detection and differentiation of Bordetella pertussis and Bordetella parapertussis in nasopharyngeal swabs
Published in Expert Review of Molecular Diagnostics, 2020
Pertussis infection, also known as whooping cough, is a severe and highly contagious respiratory illness, which is caused by the bacteria Bordetella pertussis and Bordetella parapertussis to a lesser extent. Despite high vaccination coverage in many countries for more than 65 years, B. pertussis continues to circulate producing frequent outbreaks around the world every 3 to 5 years [1,2]. In 2008, 195,000 deaths occurred worldwide [3]. Pertussis cases and deaths have been estimated to be 24.1 million cases and 160, 700 deaths globally, based on modeling studies [4]. In the U.S., the most recent outbreaks occurred in 2012–2014 in all 50 states [5].
Comparison of rapid molecular testing methods for detecting respiratory viruses in emergency care: a prospective study
Published in Infectious Diseases, 2022
Dagfinn Lunde Markussen, Harleen M. S. Grewal, Siri Tandberg Knoop, Sondre Serigstad, Øyvind Kommedal, Marit Ebbesen, Elling Ulvestad, Rune Bjørneklett
The in-house PCR provides results for Bordetella pertussis, Bordetella parapertussis, Mycoplasma pneumonia, Chlamydia pneumonia, influenza A and B, human parainfluenza viruses 1, 2 and 3, RSV, hMPV and rhinovirus. The test has been validated for samples obtained with nasopharyngeal swabs, throat swabs, sputum, bronchoalveolar lavage and bronchoscopic protected specimen brushes. In this study, only nasopharyngeal swabs and throat swabs were analysed in the in-house PCR.